EMA: Updated Q&A on Nitrosamines 2022
The European Medicines Agency (EMA) has published a revised version 12 of its Q&A on nitrosamines for marketing authorisation holders dated 10 October 2022. The revision includes an update of Q&A 10 on the limits for nitrosamines in medicinal products and introduces a new Q&A 21 on the approach to control presence of nitrosamine while the AI is being established.
Q&A 10: Which limits apply for nitrosamines in medicinal products?
- N-nitrosoduloxetine and 4-(Methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK), bothe with an acceptable intake of 100 ng/day, are now included.
Q&A 21: What is the approach to control the presence of nitrosamines until a substance specific AI is established?
- If new N-nitrosamines are identified without sufficient carcinogenicity data to establish a substance-specific limit, an AI (acceptable intake) agreed by the Non-clinical Working Party (NcWP) and adopted by the CHMP is required.
In practice, this means that when
competent authorities are notified about a product containing a new
N-nitrosamine exceeding the TTC limit of 18 ng/day, no market actions
may be required for batches with N-nitrosamine levels ≤178 ng/day at the
MDD pending the agreement of the AI.The adoption of the t-AI is not
automatic and is evaluated by the authorities at the time of
notification. Use of the t-AI beyond 12 months will require additional
consultation with competent authorities. The t-AI should not be used as a
target for development of validated analytical methods to quantify new
nitrosamines since the long-term limits adopted by CHMP might ultimately
be lower than the t-AI.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
